Dr. Husain on the Future of Monitoring T790M in Lung Cancer

Hatim Husain, MD
Published: Friday, Mar 24, 2017



Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

There is an active interest looking across both plasma and urine and better understanding how technologies in these types of spaces better anticipate resistance as well as treat resistance if it occurs, explains Husain.

It is important to find a way to chronicle how the evolution of the tumor changes and develop strategies and algorithms to better treat and combat those evolutionary pathways, states Husain.



Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

There is an active interest looking across both plasma and urine and better understanding how technologies in these types of spaces better anticipate resistance as well as treat resistance if it occurs, explains Husain.

It is important to find a way to chronicle how the evolution of the tumor changes and develop strategies and algorithms to better treat and combat those evolutionary pathways, states Husain.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x